Sensei Biotherapeutics to present SNS-103 data at conference
globenewswire.com — September 4, 2024, 09:00 PM UTC
Summary: Sensei Biotherapeutics, Inc. will present preclinical data on its investigational antibody SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference from September 8-11, 2024, in National Harbor, MD. The research focuses on monoclonal antibodies targeting CD39 in the tumor microenvironment. Sensei is developing several conditionally active therapeutics aimed at enhancing cancer treatment efficacy.
Article metrics
The article metrics are deprecated.
I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.